Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A single-center, retrospective and observational study of vedolizumab in crohn's disease (CD) and ulcerative colitis (UC) patients.

Trial Profile

A single-center, retrospective and observational study of vedolizumab in crohn's disease (CD) and ulcerative colitis (UC) patients.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Jul 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vedolizumab (Primary)
  • Indications Crohn's disease; Ulcerative colitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Jul 2018 New trial record
    • 16 Jun 2018 Results (n=171) treated with vedolizumab from July 14 to July 2017 were presented at the 19th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top